A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy

详细信息    查看全文

• 作者：Shinji Ishizuka ; Shizou Satou
• 关键词：Breast cancer ; Teratogenicity ; Goserelin acetate ; Tamoxifen
• 刊名：Breast Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：23
• 期：1
• 页码：164-166
• 全文大小：388 KB
• 参考文献：1.Nakagomi H, Haneda M, Koshizuka K, Mutou T, Takano K. Delivery of twins after undergoing adjuvant LHRH analogue and CEF therapy. Jpn J Cancer Chemother. 2003;30:519–22.
  2.Shima Y. Quantitative study on the effect of oncostatic toxicity on murine fertility. Acta Obst Gynaec Jpn. 1994;46:589–96.
  3.Esaki K, Sakai Y. Influence of oral administration of tamoxifen on the rabbit fetus. Preclin Rep Cent Inst Exp Anim. 1980;6:217–31.
  4.Fabian C, Sternson L, EL-Serafi M, Cain L, Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer. Cancer. 1981;48:876–82.PubMed CrossRef
  5.Jiménez-Gordo AM, Espinosa E, Zamora P, Feliu J, Rodriguez-Salas N, González-Barón M. Pregnancy in a breast cancer patient treated with LHRH analogue at ablative doses. Breast. 2000;9:110–2.PubMed CrossRef
  6.Cullins SL, Pridjian G, Sutherland CM. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation [Letter]. JAMA. 1994;271:1905–6.PubMed CrossRef
  7.Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero [Letter]. Lancet. 1997;350:183.PubMed CrossRef
  8.Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy—case report and literature review. Gynecol Oncol. 2001;80:405–8.PubMed CrossRef
  9.Fukuda T, Inaba I, Ooe S, Nomura H, Iinuma T, Hayashi K, et al. A case of pregnancy subsequent to mastectomy and hormonal therapy using goserelin acetate for breast cancer. Jpn J Breast Cancer. 1998;13:373–6.
  10.Hayashi E, Miyazaki A, Makihara K, Okada K, Hukino T, Hukada T. A case of delivery after mastectomy and adjuvant LH-RH treatment for a breast cancer. J Jpn Surg Assoc. 1999;60:38–41.CrossRef
  
• 作者单位：Shinji Ishizuka (1)
  Shizou Satou (2)
  
  1. Ishizuka Breast Surgery Clinic, 3-3-27 Shimoteno, Himeji, Hyogo, 670-0063, Japan
  2. Department of Surgery, Himeji Red Cross Hospital, Himeji, Hyogo, Japan
  
• 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
• 出版者：Springer Japan
• ISSN：1880-4233

文摘

In September 2000, a 32-year-old woman presented to our hospital with a right breast mass. In September 2000, she underwent pectoral muscle-preserving mastectomy for the treatment of right breast cancer. Pathologyy results revealed a mucinous carcinoma 27 × 20 × 18 mm in size accompanied by an extensive intraductal component. The tumor was staged as T2 N1M0 stage IIB and found to be estrogen receptor-positive, and 6 cycles of postoperative adjuvant chemotherapy consisting of 5-fluorouracil, epirubicin, and cyclophosphamide were carried out. Goserelin acetate plus tamoxifen was prescribed from April 2001 to March 2005. Since the patient received tamoxifen from April 2005 and eumenorrhea started in June 2006, goserelin acetate plus tamoxifen was started in August 2006. The patient was determined to be 25 weeks pregnant by abdominal ultrasonography in February 2007. This meant that she had been taking goserelin acetate plus tamoxifen for 6 months without realizing she was pregnant. She gave birth to a girl by cesarean section in May 2007. No abnormalities, including anomaly of the genitalia, were seen, and the subsequent growth of the infant was also satisfactory. We here report this case and a brief review of the literature. Keywords Breast cancer Teratogenicity Goserelin acetate Tamoxifen